Clinical grade iPS cells: need for versatile small molecules and optimal cell sources

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Molecular Biology

Background:

• Mammalian regeneration is limited, driving interest in regenerative medicine.
• Induced pluripotent stem (iPS) cell technology holds promise for tissue and organ regeneration.
• Clinical translation of iPS cells is hindered by genetic abnormalities and optimal cell source considerations.

Purpose of the Study:

• To critically review current methods and cell sources for induced pluripotent stem (iPS) cell production.
• To highlight the role of small molecules in enhancing the efficiency and safety of iPS cell generation.
• To provide a resource for researchers aiming to accelerate the clinical application of iPS cells.

Main Methods:

• Overview of various reprogramming techniques for generating iPS cells.
• Discussion of different cell sources suitable for iPS cell derivation.
• Analysis of small molecules as modulators of cellular reprogramming.

Main Results:

• Current iPS cell generation methods, including genome integration-free approaches, still present challenges.
• The choice of cell source significantly impacts the clinical applicability of iPS cells.
• Small molecules show potential for improving reprogramming efficiency and quality.

Conclusions:

• Optimizing iPS cell production requires careful consideration of both methods and cell sources.
• Small molecules are key to overcoming reprogramming barriers and achieving clinical-grade iPS cells.
• Further research into small molecule-driven reprogramming is essential for advancing regenerative medicine.